Did You Know...
...that the x-ray was discovered purely by accident? When German physicist Wilhelm Konrad von Roentgen was experimenting with cathode rays in 1895, he put an activated Crookes tube in a book and went out to lunch. When he returned, he discovered that a key that had also been placed in the book showed up as an image on the developed film!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7884181 | Pharmaceutical formulation comprising crystalline insulin and dissolved insulin The invention provides a pharmaceutical formulation and a method for preparing the formulation. ... | 02/08/2011 |
| 7875700 | Cation complexes of insulin compound conjugates, formulation and uses thereof The invention provides a complex including a cation and an insulin compound conjugate. The insulin compound conjugate includes insulin compound, such as human insulin or an analog thereof, conjugated to a modifying moiety, such as a polyethylene glycol moiety. The i... | 01/25/2011 |
| 7323543 | Multiple agent diabetes therapy A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin ana... | 01/29/2008 |
| 7279457 | Rapid acting drug delivery compositions Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous adm... | 10/09/2007 |
| 7230085 | Anti-DOTA antibody The present invention relates to an antibody or antibody fragment that binds to 1,4,7,10-tetrazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA),which is bound to an alkyl-amino group through one of its pendant carb.oxyl groups. ... | 06/12/2007 |
| 7196059 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moi... | 03/27/2007 |
| 7192919 | Sustained release compositions for delivery of pharmaceutical proteins The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein a... | 03/20/2007 |
| 7169889 | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin The present invention relates generally to hydrolyzable drug-oligomer conjugates, pharmaceutical compositions comprising such conjugates, and to methods for making and using such conjugates and pharmaceutical compositions. For example, a conjugate of insulin, PEG, a... | 01/30/2007 |
| 7122321 | High throughput method for functionally classifying proteins identified using a genomics approach The present invention provides a method for functionally classifying a protein that is capable of unfolding due to a thermal change. The method comprises screening one or more of a multiplicity of different molecules for their ability to shift the thermal unfolding ... | 10/17/2006 |
| 7084121 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. M... | 08/01/2006 |
| 7084114 | Mixtures of insulin drug-oligomer comprising polyalkylene glycol A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugate... | 08/01/2006 |
| 7084240 | Crystallization of IGF-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, opti... | 08/01/2006 |
| 7049398 | Melanocortin metallopeptide constructs, combinatorial libraries and applications Metallopeptides and metallopeptide combinatorial libraries specific for melanocortin receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and pep... | 05/23/2006 |
| 7045310 | Redox reversible bipyridyl-osmium complex conjugates Novel bipyridyl-osmium complex conjugates and their use in electrochemical assays are described. The redox reversible-osmium complexes can be prepared to exhibit unique reversible redox potentials and can thus be used in combination with other electroactive redox re... | 05/16/2006 |
| 7030084 | Drug-oligomer conjugates with polyethylene glycol components The present invention relates generally to hydrolyzable drug-oligomer conjugates, pharmaceutical compositions comprising such conjugates, and to methods for making and using such conjugates and pharmaceutical compositions. For example, a conjugate of insulin, PEG, a... | 04/18/2006 |
| 7030082 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The f... | 04/18/2006 |
| 6960561 | Zinc-free and low-zinc insulin preparations having improved stability The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of ... | 11/01/2005 |
| 6927205 | Compositions and methods for treatment of psoriasis A method for treating psoriasis of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used... | 08/09/2005 |
| 6927206 | Compositions and methods for treatment of rosacea A method for treating rosacea of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used t... | 08/09/2005 |
| 6908897 | Covalently bridged insulin dimers Provided herein is a heretofore unknown insulin analogue, a pharmaceutical composition comprising such an insulin analogue, as well as processes for preparing such an insulin analogue and such a pharmaceutical composition. ... | 06/21/2005 |
| 6906028 | Stable insulin formulations The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly adva... | 06/14/2005 |
| 6869930 | Acylated insulin The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the ... | 03/22/2005 |
| 6852694 | Stabilized insulin formulations The present invention is directed to stabilized insulin composition comprising a mixture of insulin species such as insulin and an insulin analog. As disclosed herein, insulin compositions comprising a mixture of insulin and insulin analog species form heterodimeric... | 02/08/2005 |
| 6800606 | Monomeric analogues of human insulin Monomeric analogues of human insulin have a single substitution of the amino acid in 12th, 16th or the 26th position of the B chain of human insulin and may also have a terminal deletion in the B chain. ... | 10/05/2004 |
| 6761909 | Particulate insulin-containing products and method of manufacture Provided is a compressed anti-solvent technique for manufacture of insulin-containing powders for pulmonary delivery. The insulin is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by ... | 07/13/2004 |
| 6734162 | Mixed buffer system for stabilizing polypeptide formulations The present invention is a pharmaceutical composition for polypeptide which are not stably soluble. A preferred polypeptide is monomeric insulin and a preferred formulation consists of a TRIS-phosphate combination buffer, zinc; a phenolic preservative and an isotoni... | 05/11/2004 |
| 6699673 | Protein methylarginine-specific antibodies The present invention provides antisera that specifically recognize peptides containing methylated arginines. The present invention also provides peptides for producing the antisera. Also provided is a method for the detection of methylation status of pro... | 03/02/2004 |
| 6635617 | Insulin preparations for pulmonary delivery containing menthol A stable, aqueous insulin formulation suitable for pulmonary delivery is disclosed. The formulation has increased convenience for the patient and improved bioavailability of insulin.... | 10/21/2003 |
| 6620780 | Insulin derivatives The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the -amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in t... | 09/16/2003 |
| 6566490 | Seeding crystals for the preparation of peptides or proteins Disclosed is a method for producing seeding microcrystals for the production of human insulin, the microcrystals being free of non-human pancreatic insulin, the method comprising providing an unseeded suspension of human insulin, the suspension being free... | 05/20/2003 |
| 6551992 | Stable insulin formulations The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are partic... | 04/22/2003 |
| 6531448 | Insoluble compositions for controlling blood glucose The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insu... | 03/11/2003 |
| 6521773 | Extended organic cobalt and nickel magnetic complexes Large cobalt and nickel complexes that may be linked to antibodies and other molecules are described. These may be useful in applications benefiting from their magnetic properties.... | 02/18/2003 |
| 6506731 | Elastin peptide analogs and methods of using same The present invention is directed to a composition which is used to enhance the elasticity and/or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides having low molecular weights and which substa... | 01/14/2003 |
| 6489292 | Stable aqueous insulin preparations without phenol and cresol Stable, aqueous insulin formulations without phenol and m-cresol which are suitable for pulmonary delivery and for delivery when phenol and m-cresol are undesirable are disclosed. The formulations provide increased convenience for the patient.... | 12/03/2002 |
| 6465426 | Insoluble insulin compositions The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for pare... | 10/15/2002 |
| 6451762 | Aggregates of human insulin derivatives The present invention relates-to protracted acting, water-soluble aggregates of derivatives of human insulin, derivatives of human insulin capable of forming such aggregates, pharmaceutical compositions containing them, and to the use of such aggregates i... | 09/17/2002 |
| 6432383 | Method for administering insulin A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption... | 08/13/2002 |
| 6407203 | Cytochrome c and polynucleotides encoding cytochrome c This invention is directed to cytochrome c551 polypeptides and polynucleotides encoding the polypeptides.... | 06/18/2002 |
| 6346277 | Process for the pasteurization of plasma or concentrates of blood coagulation factors II, VII, IX and X The present invention relates to a process for the preparation of a product of blood coagulation factors II, VII, IX and X which is virtually free of virus, the process comprising heating an aqueous liquid containing these factors in the presence of calci... | 02/12/2002 |
